DermTech, Inc. (DMTKQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jul 31, 2025, 8:00 PM EDT
Exscientia Revenue
DermTech had revenue of $3.85M in the quarter ending March 31, 2024, with 10.58% growth. This brings the company's revenue in the last twelve months to $15.66M, up 9.71% year-over-year. In the year 2023, DermTech had annual revenue of $15.30M with 5.36% growth.
Revenue (ttm)
15.66M
Revenue Growth
+9.71%
P/S Ratio
n/a
Revenue / Employee
75.67K
Employees
208
Market Cap
35.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 15.30M | 778.00K | 5.36% |
| Dec 31, 2022 | 14.52M | 2.68M | 22.64% |
| Dec 31, 2021 | 11.84M | 5.95M | 101.16% |
| Dec 31, 2020 | 5.89M | 2.52M | 74.94% |
| Dec 31, 2019 | 3.36M | 922.00K | 37.76% |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 84.04M |
| American Oncology Network | 1.76B |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
DermTech News
- 7 weeks ago - DERMTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating DermTech, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewsWire
- 1 year ago - DermTech Completes Transaction for Asset Sale; Operations Continue Under New Ownership and Management - Business Wire